Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Blood (2023) 142 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2023-186279

Published: 2023

Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta

Blood (2022) 140 (Supplement 1): 6945–6948.

https://doi.org/10.1182/blood-2022-164559

Published: 2022

Journal Articles

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Blood (2019) 134 (Supplement_1): 5034.

https://doi.org/10.1182/blood-2019-125595

Published: 2019

Journal Articles

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Blood (2018) 132 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2018-99-112188

Published: 2018

Journal Articles

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Blood (2018) 132 (Supplement 1): 5435.

https://doi.org/10.1182/blood-2018-99-113496

Published: 2018

Journal Articles

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Blood (2018) 132 (Supplement 1): 5118.

https://doi.org/10.1182/blood-2018-99-113273

Published: 2018

Journal Articles

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2889.

https://doi.org/10.1182/blood.V130.Suppl_1.2889.2889

Published: 2017

Journal Articles

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

Blood (2017) 130 (Supplement 1): 4973.

https://doi.org/10.1182/blood.V130.Suppl_1.4973.4973

Published: 2017

Journal Articles

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

Blood (2016) 128 (22): 3080.

https://doi.org/10.1182/blood.V128.22.3080.3080

Published: 2016

Journal Articles

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

Blood (2015) 126 (23): 1597.

https://doi.org/10.1182/blood.V126.23.1597.1597

Published: 2015

Journal Articles

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Alessandra Trojani, PhD, Ester Pungolino, MD, Milena Lodola, Barbara Di Camillo, Mariella D'Adda, MD, Alessandra Perego, MD, Mauro Turrini, MD, Chiara Elena, MD, Alessandra Iurlo, MD PhD, Cristina Buccelli, Simona Malato, MD, Francesco Spina, MD, Maria Luisa Latargia, Francesco Lanza, Sergio Pauli, MD, Michela Anghilieri, MD, Maria Cristina Carraro, Enrica Morra, MD, Roberto Cairoli, MD

Blood (2015) 126 (23): 3645.

https://doi.org/10.1182/blood.V126.23.3645.3645

Published: 2015

Journal Articles

Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib

Alessandra Trojani, Milena Lodola, Barbara Di Camillo, Giuseppe Rossi, MD, Adele Capucci, Alessandra Perego, Enrico Maria Pogliani, MD, Ester Orlandi, MD, Alessandra Iurlo, MD PhD, Simona Malato, Paolo Corradini, MD, Roberto Cairoli, Marco Bregni, Salvatore Artale, Enrica Morra, Ester Pungolino, MD

Blood (2014) 124 (21): 5177.

https://doi.org/10.1182/blood.V124.21.5177.5177

Published: 2014

Journal Articles

Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML)

Blood (2014) 124 (21): 5178.

https://doi.org/10.1182/blood.V124.21.5178.5178

Published: 2014

Journal Articles

A Pathologic Abdominal Ultrasonography At Diagnosis Of CLL Significantly Reduces The Time To Progression In Patients With Rai 0 Or Rai 1 Disease

Fausto Rossini, MD, Caterina Cecchetti, Francesca Farina, Marianna Sassone, Chiara Scollo, Sara Pezzatti, Silvia Bolis, Angelo Belotti, Sofia Bozzani, Alessandra Perego, Enrico Maria Pogliani, MD

Blood (2013) 122 (21): 2869.

https://doi.org/10.1182/blood.V122.21.2869.2869

Published: 2013

Journal Articles

Insulin-Like Growth Factor Binding Protein-3 (IGFBP3) Gene Expression In Myeloma Cell Lines and Patients

Alessandra Perego, Prerna Tewari, Mark Lawler, Paul Browne, Stephen Drain, Mark Catherwood, Giuseppe Limonta, Daniele Perego, Manuela Carrera, Enrico Maria Pogliani, MD

Blood (2010) 116 (21): 2489.

https://doi.org/10.1182/blood.V116.21.2489.2489

Published: 2010

Journal Articles

Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

Carlo B Gambacorti-Passerini, Ilaria Dilda, Giovanni Giudici, Alessandra Perego, Francesca Pavesi, Luca Guerra, Lorenza Borin, Ivana Casaroli, Marilena Fedele, Luisa Verga, Enrico Maria Pogliani

Blood (2010) 116 (21): 2877.

https://doi.org/10.1182/blood.V116.21.2877.2877

Published: 2010

Journal Articles

The Risk of Progression in 127 Early Stage CLL Patients. Prognostic Significance of Mutational Status, ZAP-70 and CD-38.

Alessandra Perego, MD, Fausto Rossini, MD, Daniele Perego, MD, Andrea Soccodato, MD, Pierluigi Tramacere, MD, Chiara Colombo, Fabio Rossi, MD, Tiziana Speranza, Paolo Mocarelli, MD, Enrico Maria Pogliani, MD

Blood (2006) 108 (11): 4937.

https://doi.org/10.1182/blood.V108.11.4937.4937

Published: 2006

NARROW

Improved Overall Survival Among Luspatercept Responders and Predictors of Response

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Jak-2 and Nfkbia G ene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

The REL-Protocol PhilosoPhi34 - an Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) Patients - Confirms Early Clearance of Bone Marrow CD34+/Lin-Ph+ Cells

REL-Protocol PhilosoPhi34: An Open Label, Single Arm, Phase II Study of Nilotinib 300 Mg BID in Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia Patients, to Study the Disappearance of CD34+/Lin-Ph+ Cells from Bone Marrow during Treatment. Preliminary Data

GEP Analyses of Bone Marrow CD34+/Lin- Cells of Chronic Phase CML Patients at Diagnosis Identified Different Sets of Genes Associated to the Molecular Response after 3 and 6 Months of First-Line Nilotinib Treatment

Gene Expression Profiling of CD34+/Lin- Cells of Patients with Chronic Myeloid Leukemia at Diagnosis and after 12 Months of Nilotinib

Microarray of Bone Marrow CD34+/Lin- Cells from Patients with Chronic Myeloid Leukemia (CML)

A Pathologic Abdominal Ultrasonography At Diagnosis Of CLL Significantly Reduces The Time To Progression In Patients With Rai 0 Or Rai 1 Disease

Insulin-Like Growth Factor Binding Protein-3 (IGFBP3) Gene Expression In Myeloma Cell Lines and Patients

Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients

The Risk of Progression in 127 Early Stage CLL Patients. Prognostic Significance of Mutational Status, ZAP-70 and CD-38.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only